Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
10:56am, Friday, 03'rd May 2024
The mean of analysts' price targets for Kymera Therapeutics (KYMR) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
05:07am, Friday, 03'rd May 2024
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Presiden
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
07:00am, Thursday, 02'nd May 2024
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Thursday, 25'th Apr 2024
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
07:00am, Thursday, 25'th Apr 2024
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
07:00am, Monday, 08'th Apr 2024
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
04:28pm, Thursday, 21'st Mar 2024
Kymera Therapeutics' shares have dropped from $81 to $39 since my note back in 2021, but have risen >130% in the past 6m. The company's technology targets the ubiquitin proteasome system to degrade di
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Wednesday, 28'th Feb 2024
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
07:00am, Thursday, 22'nd Feb 2024
KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Thursday, 15'th Feb 2024
Kymera Therapeutics, Inc. (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
07:00am, Thursday, 15'th Feb 2024
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
07:00am, Wednesday, 31'st Jan 2024
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
09:17am, Tuesday, 09'th Jan 2024
IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
